Genscript Biotech Corporation (G51) — Financial Flexibility Index
Genscript Biotech Corporation (G51) has a Financial Flexibility Index of -0.04x as of June 2023. Free cash flow of €-53.49 Million (operating CF €-93.58 Million minus capex €40.10 Million) represents 0% of total liabilities (€1.30 Billion). Check how strategically is Genscript Biotech Corporation's equity deployed to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Genscript Biotech Corporation Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Genscript Biotech Corporation across 10 annual periods. See Genscript Biotech Corporation short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Genscript Biotech Corporation (2016–2025)
Year-by-year free cash flow to debt coverage for Genscript Biotech Corporation. For the full company profile including market capitalisation, see G51 stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.46x | €409.36 Million | €325.52 Million | €888.59 Million | ▲ +96.8% |
| 2024 | 0.23x | €223.57 Million | €75.65 Million | €954.91 Million | ▲ +343.4% |
| 2023 | -0.10x | €-129.20 Million | €-286.91 Million | €1.34 Billion | ▼ -236.7% |
| 2022 | 0.07x | €83.28 Million | €-120.29 Million | €1.18 Billion | ▲ +2240.7% |
| 2021 | 0.00x | €-3.75 Million | €-136.79 Million | €1.14 Billion | ▲ +92.9% |
| 2020 | -0.05x | €-29.21 Million | €-151.09 Million | €631.82 Million | ▼ -129.7% |
| 2019 | 0.16x | €80.42 Million | €-29.95 Million | €517.11 Million | ▼ -82.6% |
| 2018 | 0.89x | €378.50 Million | €307.66 Million | €423.68 Million | ▲ +387.4% |
| 2017 | 0.18x | €50.58 Million | €21.37 Million | €275.94 Million | ▼ -81.8% |
| 2016 | 1.01x | €42.26 Million | €33.27 Million | €42.01 Million | — |